Roche’s Tecentriq (atezolizumab) Combination Therapy Receives Health Canada’s Approval for Metastatic Non-Squamous Non-Small Cell Lung Cancer in Adults

 Roche’s Tecentriq (atezolizumab) Combination Therapy Receives Health Canada’s Approval for Metastatic Non-Squamous Non-Small Cell Lung Cancer in Adults

Roche’s Tecentriq (atezolizumab) + Abraxane Receive European Commission’s Approval for Patients with PD-L1-Positive Metastatic Triple-Negative Breast Cancer

Shots:

  • The approval is based on P-III IMpower150 study results assessing Tecentriq + CT (carboplatin and paclitaxel) with/without Avastin (bevacizumab) vs Bevacizumab and CT in 1,202 patients in a ratio (1:1:1) with stage IV recurrent metastatic non-sq NSCLC, no prior treatment with CT
  • The P-III IMpower150 study results: OS (19.2 vs 14.7 mos.); no new safety signals are observed
  • Tecentriq is a mAb targeting PD-L1 expressing tumor cells when combined with bevacizumab + CT enhances its ability to restore anti-cancer immunity to combat 1L advanced NSCLC

Click here to read full press release/ article | Ref: PRNewswire | Image: Idworksglobal

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post